What price target do analysts set for Teva?
What price target have analysts set for TEVA? 10 brokerages have issued 1-year target prices for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $14.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $11.25 in the next twelve months.
How do you buy shares of Teva stock?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
How does Teva Pharmaceutical Industries'news coverage rank on infotrie?
The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a news impact score of -1.7 on InfoTrie's scale.
See more
When will Teva release its results for 2021?
(NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the second quarter of 2021 on Wednesday, July 28, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
What did the Supreme Court say about Abbvie?
Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel. The justices turned away AbbVie's appeal and left intact the lower court's finding that its 2011 complaint against Perrigo was brought solely to delay Perrigo's proposed generic version of AndroGel. The Philadelphia-based 3rd U.S. Circuit Court of Appeals last year threw out a federal judge's order requiring AbbVie and partner Besins Pharmaceuticals to disgorge $448 million in profits to the Federal Trade Commission, but found that the judge had correctly determined that they had violated antitrust law.
When is the Cobra study?
AMSTERDAM, Jun 22, 2021--The COBRA study, a new real world evidence study undertaken by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital (Bochum, Germany), was presented today at EAN congress and provided new insight on the use of COPAXONE® (glatiramer acetate or GA) by mothers with multiple sclerosis (MS) who are breastfeeding.
Is topotecan recalled?
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is recalling one lot of its cancer drug topotecan injection after a pharmacy complaint flagged the presence of a single glass particulate in a vial of the drug. A follow-up review of the suspect sample turned up two other particles, which have been identified as grey silicone and “translucent, colorless cotton fiber,” a notice on the FDA’s website said. Teva notified its customers on June 18 and asked that the lot be recalled. It said it hadn’t rec
When will Teva release its earnings?
Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021. View our earnings forecast for Teva Pharmaceutical Industries.
When is Teva earnings call?
Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, July 28th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 866-331-1332 with passcode "9693275".
